Last reviewed · How we verify

NCT04978805: Progressive

Progressive Relaxation Exercise on Dyspnea, Pain and Sleep Quality

Completed NA Last updated 31 August 2023
What this trial tests

NA trial testing Progressive Relaxation Exercise in Cancer in 60 participants. Completed in 31 August 2021.

Timeline
1 April 2021
Primary endpoint
1 June 2021
31 August 2021

Quick facts

Lead sponsorIstanbul Sabahattin Zaim University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment60
Start date1 April 2021
Primary completion1 June 2021
Estimated completion31 August 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Sabahattin Zaim University

Who can join

Adults 18 to 65, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was planned to examine the effect of progressive relaxation exercises applied to lung cancer patients receiving chemotherapy on dyspnea, pain and sleep quality.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The effects of progressive muscle relaxation exercise applied to lung cancer patients receiving chemotherapy on dyspnea, pain and sleep quality: A randomized controlled trial.
    Turan GB, Özer Z, Sariköse A. · · 2024 · cited 6× · PMID 38636116 · DOI 10.1016/j.ejon.2024.102580

Verify or expand the search:

Other trials of Progressive Relaxation Exercise

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Istanbul Sabahattin Zaim University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04978805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing